Dynamics of Donor-Derived Cell-Free DNA at the Early Phase After Pediatric Kidney Transplantation: A Prospective Cohort Study

Weijian Nie1†, Xiaojun Su1†, Longshan Liu1,2,3†, Jun Li1, Qian Fu1, Xirui Li1, Chenglin Wu1, Jiali Wang1, Ronghai Deng1, E. Chen1, Shicong Yang5, Shujuan Li6, Huanxi Zhang1* and Changxi Wang1,2,3*

1 Organ Transplant Center, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China, 2 Guangdong Provincial Key Laboratory on Organ Donation and Transplant Immunology, Guangzhou, China, 3 Guangdong Provincial International Cooperation Base of Science and Technology (Organ Transplantation), Guangzhou, China, 4 Department of Nephrology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China, 5 Department of Pathology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China, 6 Department of Cardiovascular Pediatrics, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China

Background: Donor-derived cell-free DNA (ddcfDNA) has been suggested as an indicator of allograft injury in adult and pediatric kidney transplantation (KTx). However, the dynamics of ddcfDNA in pediatric KTx have not been investigated. In addition, it has not been demonstrated whether donor-recipient (D/R) size mismatch affect ddcfDNA level.

Methods: Pediatric KTx recipients with a single donor kidney were enrolled and followed up for 1 year. ddcfDNA, calculated as a fraction (%) in the recipient plasma, was examined longitudinally within 3 months post-transplant. D/R size mismatch degree was described as D/R height ratio. The 33rd percentile of D/R height ratio (0.70) was used as the cut-off to divide the patients into low donor-recipient height ratio group (<0.70) and high donor-recipient height ratio group (≥0.70). The dynamics of ddcfDNA were analyzed and the impact factors were explored. Stable ddcfDNA was defined as the first lowest ddcfDNA. ddcfDNA flare-up was defined as a remarkable elevation by a proportion >30% from stable value with a peak value >1% during elevation.

Results: Twenty-one clinically stable recipients were enrolled. The median D/R height ratio was 0.83 (0.62–0.88). It took a median of 8 days for ddcfDNA to drop from day 1 and reach a stable value of 0.67% (0.46–0.73%). Nevertheless, 61.9% patients presented ddcfDNA >1% at day 30. Besides, 81.0% (17/21) of patients experienced elevated ddcfDNA and 47.6% (10/21) met the standard of ddcfDNA flare-up. Donor-recipient height ratio was an independent risk factor for ddcfDNA flare-up (odds ratio = 0.469 per 0.1, 95% CI 0.237–0.925, p = 0.029) and low donor-recipient height ratio (<0.70) was found to increase the risk of flare-up occurrence (odds ratio = 15.00, 95% CI 1.342–167.638, p = 0.028).
Kidney transplantation (KTx) is the most effective treatment for children with end-stage renal disease (ESRD) (1, 2). However, long-term outcome of pediatric kidney transplantation is unsatisfactory and the 10-year graft survival rate is only about 60% (3). Antibody-mediated rejection (ABMR) is a crucial factor in poor long-term graft survival in both pediatric and adult kidney transplantation (4, 5). Despite increasing understanding of its pathogenesis, few sensitive and effective biomarkers are available for monitoring and diagnosis of ABMR. Renal allograft biopsy, though remaining the gold standard diagnosis of rejection, is infrequently used for surveillance because of the cost and its potential invasive complications (6). The conventional non-invasive parameters such as serum creatinine, cystatin C, and proteinuria are not sensitive and often lag renal allograft injury, leading to missed or delayed diagnosis of ABMR, and thus impact long-term graft outcome (7, 8). Accurate, reproducible, and timely non-invasive biomarkers to monitor graft injury and rejection are urgent to improve long-term transplant outcome.

Donor-derived cell-free DNA (ddcfDNA) has emerged as a potential and promising biomarker for early detection of graft injury and rejection. The ddcfDNA level above 1% strongly correlates with acute rejection (9). Accompanied with donor specific antibody (DSA), ddcfDNA could significantly improve the diagnosis efficiency of active ABMR (10). The utilization of ddcfDNA can better diagnose acute rejection and complement the Banff classification to treat subclinical rejection. High level of ddcfDNA has been proved to reveal subclinical graft injury caused by inadequate immunosuppression, while low level of ddcfDNA indicates absence of significant graft injury and thus facilitates to avoid unnecessary kidney biopsy (11). In patients with biopsy-proven early T cell-mediated rejection (TCMR), including Banff TCMR 1A and borderline lesions, ddcfDNA level could help risk stratification (12). The elevated ddcfDNA in those patients predicted adverse clinical outcomes including declined estimated glomerular filtration rate (eGFR), de novo DSA (dnDSA) formation and future rejection (12).

A high amount of ddcfDNA is released into peripheral circulation immediately after renal allograft reperfusion mainly due to ischemia-reperfusion injury (IRI), followed by a swift decrease to a stable low level (13). It’s important to investigate the dynamics of ddcfDNA, especially in the early post-transplant period, as it is helpful to better interpret the clinical significance of ddcfDNA results, e.g., discrimination of IRI and rejection. Contrary to the accumulating data of ddcfDNA in adult KTx, only one study exploring ddcfDNA in pediatric KTx has been reported. Puliyanda et al. provided the evidence that ddcfDNA could be a useful indicator for identifying acute rejection in pediatric kidney transplantation (14). The dynamics of ddcfDNA in pediatric KTx, which may be different from that in adult KTx, has not been well-investigated. Many factors affect the level of ddcfDNA, such as infection and multiple organ transplantation. The fraction of ddcfDNA decreases in a recipient with infection mainly because of elevated white blood cell counts (15), while increases in a recipient with longer cold ischemia time (13, 16). It has not been demonstrated whether donor-recipient size mismatch affect ddcfDNA level. Pediatric kidney transplant program has developed fast during the past decades (5). Many pediatric donor kidneys are utilized for transplantation to pediatric recipients, which leads to variable donor-recipient (D/R) size mismatch (17–20). Since D/R size mismatch is considered to cause hyperfiltration injury (21), we hypothesized that the level of ddcfDNA, an indicator of allograft injury, may be affected by donor-recipient size mismatch. Therefore, the Pediatric kidney transplantation Cell-free DNA Trial (Pedi-ceft Study), was conducted to firstly demonstrate the dynamics of ddcfDNA in pediatric recipients early after kidney transplantation, and more importantly to explore its impact factors with especial attention to D/R size mismatch.

** MATERIALS AND METHODS**

**Study Design**

This is a single-center prospective cohort study conducted in the First Affiliated Hospital of Sun Yat-sen University. Children who received primary pediatric deceased-donor-kidney transplantation between December 2019 and June 2020 were consecutively investigated. All enrolled pediatric recipients were scheduled to receive sequential ddcfDNA detection within 3 months and were followed up for 1 year. Patients with post-transplant complications within 3 months including graft loss, rejection, and polyomavirus-associated nephropathy were
excluded. Patients with substandard specimen quality and those who were unable to finish 1-year follow-up were also excluded.

All patients and their legal representatives provided written informed consents for participation in the study. This study was approved by the institutional review board of the First Affiliated Hospital of Sun Yat-sen University and was registered at the official national Chinese Clinical Trial Registry (No. ChiCTR2000032333). This study was conducted in accordance with the principles of the World Medical Association Declaration of Helsinki and the declaration of Istanbul. No organs were from executed prisoners.

**ddcfDNA Measurements**

Blood (8 mL) samples were drawn from enrolled patients using customized cfDNA blood collection tubes (Streck, Omaha, NE). Plasma was separated by centrifugation at 1,600 × g for 10 min followed by a second centrifugation at 16,000 × g for another 10 min. Plasma cfDNA was extracted with Circulating Nucleic Acid kit (Cat. No. 55114, QiaGen) and whole blood genomic DNA was extracted with DNA Blood mini kit (Cat. No. 51104, QiaGen). Purified DNA was quantified by Qubit 3.0 using the dsDNA HS Assay Kit (Life Technologies). Sequencing libraries were prepared by applying KAPA Hyper Prep kit (KAPA Biosystems) with 30 ng of input DNA. A total of 6,200 human single nucleotide polymorphism (SNP) loci were enriched by liquid hybridization based on SNP loci selection criteria (13). All sequencing was performed on the Illumina X-ten next generation sequencing (NGS) platform (10 ± 5 million, PE 150 bp). Sequencing data were processed as previously described (13).

In brief, the SNP genotype of the recipient was determined by whole blood genomic DNA sequencing. Assuming that “a” is the donor genotype, the effective SNP sites that could be used for subsequent quantification including the recipient genotype, which was designated “AA,” and the donor genotype “Aa” or “aa,” were used to calculate the proportion distribution of donor SNP by the value of a/(A+a). According to the proportion of donor genotype “a” in the effective SNP, the fraction of ddcfDNA level was calculated based on Bayes approach.

**Parameters of ddcfDNA Dynamics**

The ddcfDNA level was examined longitudinally and ddcfDNA fraction (%) was determined at day 1, day 4, day 7, day 14, day 30, day 60, and day 90, within an acceptable time window for each time point. Dynamic change of ddcfDNA was explored and depicted.

Stable ddcfDNA was defined as the first lowest ddcfDNA value after transplantation. Elevation of ddcfDNA was observed in a proportion of study subjects after reaching the stable level. Therefore, the dynamic characteristics of ddcfDNA elevation was especially described as the followings. The occurrence time of ddcfDNA elevation was presumed as the previous detection time point before its elevation, and therefore it was the same as the time point when ddcfDNA reached a stable level. The duration of ddcfDNA elevation was counted as the period from occurrence of ddcfDNA elevation to its peak level. Peak ddcfDNA was the highest level of ddcfDNA during the elevation. The proportion of ddcfDNA change from stable level to peak level was calculated as (peak ddcfDNA – stable ddcfDNA)/stable ddcfDNA. Slight fluctuation in ddcfDNA was justified and considered as random intra-patient variations (11), whereas remarkable ddcfDNA elevation was considered abnormal and quantified using a parameter named FLARE-UP. Flare-up was defined when ddcfDNA elevated by over 30% from stable level as well as the peak level was over 1% during elevation. One percent was used as the threshold of flare-up because it was often used for the diagnosis of rejection and impaired renal allograft function in prior studies (14).

**Clinical Parameters and Clinical Events**

The pre- and post-transplant demographics and clinical data of donors and recipients, including gender, age, height, weight, body surface area (BSA), human leukocyte antigen (HLA) mismatch, donor type, cold ischemia time (CIT), donor-recipient size mismatch, and immunosuppressive therapy were recorded. The size of child is often assessed by weight, height or BSA. BSA was calculated using Stevenson's BSA formula (22): BSA (m²) = 0.0061 × height (cm) + 0.0128 × weight (kg) – 0.1529. In pediatric patients with kidney disease, height is preferred because ascites, edema or other complications can significantly affect weight. In this study, D/R size mismatch degree was described by the ratio of donor height to recipient height (23, 24). The 33rd percentile of D/R height ratio (0.70) was used as the cut-off to divide the patients into low D/R height ratio group (<0.70) and high D/R height ratio group (≥0.70).

Delayed graft function (DGF) was defined as the need for dialysis within the first week post-transplant. All recipients received tacrolimus as a part of the maintenance immunosuppression regimen. Tacrolimus trough levels were measured at least once a week in the first month, every 2–3 weeks in 2–3 months, every 4–6 weeks in 4–6 months, and every 1–2 months after 6 months. In addition, the frequency of detection was adjusted according to the clinical condition. The tacrolimus target trough level was 6.0–10.0 ng/mL in the first month, 5.0–9.0 ng/mL within 3 months, and 5.0–8.0 ng/mL thereafter. The estimated glomerular filtration rate (eGFR) calculated with Schwartz formula was used for assessment of kidney graft function (25, 26). Within 3 months post-transplant, eGFR was calculated and recorded weekly, and after that once per month. Graft ultrasound examination was longitudinally implemented during the follow-up, and the length of the kidney was measured to observe graft growth. Within the first 3 months post-transplant, at least one ultrasound examination was performed, and indicalional ultrasound examination was performed after that. The proportion of graft growth was calculated as (kidney length after 3 months – kidney length within 3 months)/kidney length within 3 months.

All enrolled recipients were followed up for at least 1 year. Post-transplant complications including dnDSA, rejection and BK polyomavirus-associated nephropathy (BKVN) were prospectively recorded. After transplantation, DSA detection was conducted monthly within the first 3 months and every 3 months after that. Diagnosis of rejection and BKVN was confirmed by renal allograft biopsy following the 2018 Banff criteria (27). Patients with stable eGFR (eGFR increased by <15% compared...
to the previous eGFR), and without dnDSA, were considered clinically stable. Those with eGFR increased by over 15% in two-consecutive detection were advised to receive kidney biopsy. The ddcfDNA results were blinded to transplant physicians therefore no intervention would be exerted on patients with increased or abnormal ddcfDNA measurements.

Statistical Analysis
Continuous data were presented as median (lower quartile-upper quartile) if not especially mentioned. Categorical data were reported as counts and percentages. Statistical analysis was performed using IBM SPSS Statistics version 22.0 (IBM Corporation, New York, USA), R version 4.0.3 (https://www.r-project.org) and GraphPad Prism 7 (GraphPad Software, La Jolla, CA). Comparisons between groups were performed using Mann-Whitney U-test for continuous variables and Chi-square test or Fisher’s exact test for categorical variables. Spearman correlation test was used to test correlation between variables. Logistic regression was used for the univariable and multivariable analysis of risk factors for ddcfDNA flare-up and post-transplant outcomes. Linear regression was used for univariable and multivariable analysis of stable ddcfDNA, ddcfDNA at day 90, occurrence time and duration time of ddcfDNA elevation. The variables with $P < 0.10$ in the univariable analysis were enrolled in the multivariable model. Demographic and clinical characteristics of recipients and donors, including donor-recipient size mismatch degree, were included as the independent variables in the regression models. Dynamics parameters of ddcfDNA were included in the regression models for post-transplant outcomes. Adjusted $R^2$ square and Somer’s Delta were used for model performance evaluation. For all analyses, a $P < 0.05$ was considered statistically significant.

RESULTS
Patient Demographics
The flow diagram of recruitment and exclusion of study participants was shown in Figure 1. A total of 32 recipients were eligible for inclusion in the study. According to the exclusion criteria, 10 patients were excluded while one patient was withdrawn from analysis because of substandard blood specimen quality. Thus, 21 recipients were eventually enrolled in the analysis. One recipient had pre-transplant panel reactive antibodies (HLA class I antibody 3%). No recipient showed pre-transplant DSA and was diagnosed with dDNA within 3 months post-transplant. According to graft function and DSA status, all the 21 recipients were clinically stable. The demographic and clinical characteristics of donors and recipients were summarized in Table 1. The median donor-recipient height ratio was 0.83 (0.62–0.88). The median weight and height of donors were 15 (13–21) kg and 102 (90–120) cm, respectively, while the median weight and height of recipients were 31 (18.5–38.5) kg and 137 (115–150) cm. All kidneys were from deceased donors and eight (35.1%) of them were from donation after circulatory death (DCD). All recipients received tacrolimus + corticosteroid + mycophenolic acid (MPA) as maintenance. The median tacrolimus trough levels in 3 months post-transplant were within the window between 6.0 and 9.0 ng/ml (Supplementary Figure 1).
### TABLE 1 | Demographic and clinical characteristics.

|                         | All (N = 21) | Flare-up (N = 10) | Non-flare-up (N = 11) | P-value |
|-------------------------|--------------|-------------------|-----------------------|---------|
| **Recipient**           |              |                   |                       |         |
| Age (years old, IQR)    | 11.0 (7–13)  | 12 (9.3–13.8)     | 11 (5.5–11.5)         | 0.147   |
| Male (n, %)             | 11 (52.4%)   | 7 (70.0%)         | 4 (36.4%)             | 0.198   |
| Height (cm, IQR)        | 137 (115–150)| 143 (132.8–150)   | 123 (110–150.5)       | 0.324   |
| Weight (kg, IQR)        | 31 (18.5–38.5)| 33.4 (25.5–39)    | 30 (17.1–37.3)        | 0.622   |
| BSA (m², IQR)           | 1.09 (0.76–1.24)| 1.16 (1.00–1.22)  | 0.98 (0.73–1.27)      | 0.622   |
| **Blood type**          |              |                   |                       | 0.119   |
| O (n, %)                | 8 (38.1%)    | 3 (30.0%)         | 5 (45.5%)             |         |
| B (n, %)                | 8 (38.1%)    | 3 (30.0%)         | 5 (45.5%)             |         |
| A (n, %)                | 4 (19.0%)    | 4 (40%)           | 0%                    |         |
| AB (n, %)               | 1 (4.8%)     | 0%                | 1 (9.1%)              |         |
| Pre-transplant transfusion (n, %) | 10 (47.6%) | 6 (60.0%)         | 4 (36.4%)             | 0.395   |
| **Dialysis**            |              |                   |                       | 0.183   |
| Yes (n, %)              | 16 (76.2%)   | 5 (50.0%)         | 9 (81.8%)             |         |
| No (n, %)               | 5 (23.8%)    | 5 (50.0%)         | 2 (18.2%)             |         |
| **Dialysis time (years, IQR)** | 0.63 (0–1.37) | 0.43 (0–1.12) | 0.63 (0.33–2.09) | 0.282 |
| Pre-transplant PRA (n, %) | 1 (4.8%)    | 0%                | 1 (9.1%)              | 1.000   |
| Pre-transplant DSA (n, %) | 0%          | 0%                | 0%                    | 1.000   |
| **HLA mismatch**        |              |                   |                       | 0.949   |
| 2 (n, %)                | 3 (14.3%)    | 2 (20.0%)         | 1 (9.1%)              |         |
| 3 (n, %)                | 2 (9.5%)     | 1 (10.0%)         | 1 (9.1%)              |         |
| 4 (n, %)                | 4 (19.0%)    | 2 (20.0%)         | 2 (18.2%)             |         |
| 5 (n, %)                | 10 (47.6%)   | 4 (40.0%)         | 6 (45.5%)             |         |
| 6 (n, %)                | 2 (9.5%)     | 1 (10.0%)         | 1 (9.1%)              |         |
| **Primary disease**     |              |                   |                       | 0.373   |
| Hereditary renal disease (n, %) | 8 (19.0%) | 2 (20.0%)         | 6 (55.4%)             |         |
| CAKUT (n, %)            | 5 (23.8%)    | 3 (30.0%)         | 2 (18.2%)             |         |
| Glomerulonephritis (n, %) | 1 (4.8%)    | 1 (10.0%)         | 0%                    |         |
| Interstitial nephritis (n, %) | 1 (4.8%) | 1 (9.1%)          | 0%                    |         |
| Lupus nephritis (n, %)  | 1 (4.8%)     | 1 (10.0%)         | 0%                    |         |
| Unidentified (n, %)     | 3 (14.3%)    | 2 (20.0%)         | 3 (27.3%)             |         |
| **Donor**               |              |                   |                       |         |
| Age (years old, IQR)    | 3 (2–8)      | 3.5 (2–6)         | 3 (2–8)               | 0.915   |
| Male (n, %)             | 16 (76.2%)   | 7 (70.0%)         | 9 (81.8%)             | 0.635   |
| Height (cm, IQR)        | 102 (90–120) | 90 (73.8–103)     | 120 (90.5–124)        | 0.096   |
| Weight (kg, IQR)        | 15 (13–21)   | 14.5 (12.2–17.8)  | 15.0 (13.0–22.0)      | 0.596   |
| BSA (m², IQR)           | 0.66 (0.56–0.87)| 0.60 (0.42–0.69)  | 0.75 (0.57–0.88)      | 0.180   |
| **Donor type**          |              |                   |                       | 0.080   |
| DBD (n, %)              | 13 (61.9%)   | 4 (40.0%)         | 9 (81.8%)             |         |
| DCD (n, %)              | 8 (35.1%)    | 6 (60.0%)         | 2 (18.2%)             |         |
| **Cold ischemia time (hours, IQR)** | 9 (8–12.5) | 10.5 (8.6–12.5) | 8.5 (7.8–9)          | 0.215   |
| **D/R size mismatch**   |              |                   |                       |         |
| D/R height ratio (IQR)  | 0.83 (0.62–0.88)| 0.60 (0.58–0.82)  | 0.84 (0.78–1.05)      | 0.017   |
| D/R weight ratio (IQR)  | 0.67 (0.48–0.93)| 0.57 (0.43–0.70)  | 0.70 (0.54–0.93)      | 0.192   |
| D/R BSA ratio (IQR)     | 0.72 (0.52–0.85)| 0.51 (0.46–0.77)  | 0.83 (0.66–0.95)      | 0.024   |
| **Induction therapy**   |              |                   |                       | 0.586   |
| IL-2RA (n, %)           | 18 (85.7%)   | 8 (80.0%)         | 10 (90.9%)            |         |
| ATG (n, %)              | 3 (14.3%)    | 2 (20.0%)         | 1 (9.1%)              |         |
TABLE 1 | Continued

| Maintenance therapy | All (N = 21) | Flare-up (N = 10) | Non-flare-up (N = 11) | P-value |
|---------------------|-------------|------------------|----------------------|---------|
|                     |             |                  |                      |         |
| Tacrolimus + Corticosteroid + MPA |             |                  |                      |         |
| MMF (n, %)          | 15 (71.4%)  | 5 (50.0%)        | 10 (90.9%)           | 0.063   |
| EC-MPS (n, %)       | 6 (28.6%)   | 5 (50.0%)        | 1 (9.09%)            |         |
| DGF (n, %)          | 3 (14.3%)   | 2 (20.0%)        | 1 (9.09%)            | 0.456   |

ATG, anti-thymocyte globulin; BSA, body surface area; CAKUT, congenital anomalies of the kidney and urinary tract; DBD, donation after brain death; DCD, donation after circulatory death; DGF, delayed graft function; D/R, recipient-donor; DSA, donor specific antibody; EC-MPS, enteric-coated mycophenolate sodium; HLA, human leukocyte antigen; IL-2RA, Interleukin 2 receptor antibody; IQR, interquartile range; MMF, mycophenolate mofetil; MPA, mycophenolic acid; PRA, panel reactive antibodies.

TABLE 2 | ddcfDNA dynamic parameters.

| ddcfDNA at each time point | Analyzed patients (N = 21) |
|----------------------------|---------------------------|
| ddcfDNA at day 1 (%, IQR)  | 5.4% (2.25–7.89%)          |
| ddcfDNA at day 4 (%, IQR)  | 1.49% (0.74–2.73%)         |
| ddcfDNA at day 7 (%, IQR)  | 1.15% (0.61–1.76%)         |
| ddcfDNA at day 14 (%, IQR) | 1.08% (0.73–1.39%)         |
| ddcfDNA at day 30 (%, IQR) | 0.90% (0.71–0.85%)         |
| ddcfDNA at day 60 (%, IQR) | 0.64% (0.47–0.85%)         |
| ddcfDNA at day 90 (%, IQR) | 0.63% (0.46–0.86%)         |
| Stable ddcfDNA (%, IQR)³  | 0.67% (0.46–0.73%)         |
| ddcfDNA stable time (days, IQR) | 8 (5–14) |
| Exact time of day 1 (hours, IQR) | 26 (12–28) |
| ddcfDNA elevation | 17 (81.0%) |
| Flare-up (n, %)² | 10 (47.6%) |
| Elevation occurrence time post-operation (days, IQR) | 6 (5–13) |
| Elevation duration (days, IQR) | 10 (3–42) |
| Peak ddcfDNA during elevation (%, IQR) | 1.27% (0.88–1.93%) |
| Proportion of ddcfDNA change during elevation (%, IQR) | 80% (66–144%) |

ddcfDNA, donor-derived cell-free DNA; IQR, interquartile range.
³Stable ddcfDNA was defined as the first lowest ddcfDNA.
²Flare-up was defined as a post-stable elevation in ddcfDNA by over 30% from stable with a peak of over 1% during elevation.

Impact Factors of ddcfDNA Dynamics

Linear analysis in Table 3 demonstrated the potential factors affecting the stable ddcfDNA. An increase in donor weight, donor height, donor BSA, donor age, or female donor, was associated with elevated stable ddcfDNA in univariable analysis. However, the five parameters showed severe multicollinearity and thus were not appropriate for multiple regression. The adjusted R square values of the univariable linear models with donor weight, height, BSA, gender, and age were 0.382, 0.120, 0.255, 0.368, and 0.131 respectively, indicating that donor weight had the highest explainable level in the linear model (β coefficient = 0.017 per 1 kg, 95% CI 0.007–0.026, P = 0.002). The potential impact factors of ddcfDNA at day 90, the occurrence time and duration time of ddcfDNA elevation were summarized in Supplementary Table 1. Longer CIT and DCD donor was associated with increased ddcfDNA (%) at day 90. Due to the strong correlation between these two variables, it was unavailable to put them in to a multiple regression model. CIT had a higher explainable level in the model compared with donor type (adjusted R square, 0.358 vs. 0.311). Besides, DCD donor was found significantly correlated with the duration time of elevation (β coefficient = 35.352, CI: 13.317–57.386, p = 0.003).

The comparisons of flare-up and non-flare-up group were shown in Table 1. Donor-recipient height ratio was significantly lower in the flare-up group than that in non-flare-up group (Table 1, median 0.61 vs. 0.84, p = 0.017). Factors including D/R height ratio, donor height, donor type, MPA type, and D/R BSA ratio were potential risk factors (P < 0.10). D/R height ratio, donor type and MPA type were included in the multivariable analysis of flare-up while donor height and D/R BSA ratio were excluded due to the correlations with D/R height ratio. The potential risk factors on flare-up were investigated by univariable and multivariable analysis in Table 4. Model 2 showed that higher D/R height ratio was associated with lower
Nie et al. ddcfDNA Dynamics After Pediatric KTx

FIGURE 2 | ddcfDNA at different time during the study period. (A) ddcfDNA change within 3 months. The boxes displaying ddcfDNA after day 4 was zoomed in and the elevation of ddcfDNA level could be indicated; (B) distribution proportion of 21 clinically stable patients with ddcfDNA >1% at different time post-transplant. The black bar depicts patients with ddcfDNA >1%; the gray bar depicts patients with ddcfDNA ≤1%; (C) ddcfDNA at different time (after day 1) in the ten patients with ddcfDNA flare-up. All the boxes depict the 25th and 75th percentiles as a box and a median line; whiskers extend to minimum or maximum. ddcfDNA, donor-derived cell-free DNA.

risk of flare-up occurrence (odds ratio = 0.469 per 0.1, 95% CI: 0.237–0.925, p = 0.029). Recipients were divided into low D/R height ratio (≤0.70) and high D/R height ratio group (≥0.70) according to the 33rd percentile of D/R height ratio (0.70). Model 1 indicated that low D/R height ratio increased the risk of flare-up occurrence (odds ratio = 15.00 low vs. high, 95% CI: 1.342–167.638, P = 0.028) compared with the high ratio group. The multivariable model 3 and 4 in Table 4 showed that after the adjustments, the effect of D/R height ratio on flare-up remained statistically significant, indicating that D/R height ratio was an independent risk factor for the occurrence of flare-up. The length of renal allograft gradually increased after transplantation, and the median proportion of increased kidney length (graft growth) was 20.0% (6.4–23.5%) after 3 months post-transplant. In addition, the proportion of graft growth was negatively correlated with donor-recipient height ratio (r = −0.506, p = 0.034, Figure 3).

Post-transplant Outcomes
Post-transplant outcomes of the enrolled patients were summarized in Supplementary Table 2. Three patients were diagnosed with biopsy-proven acute rejection after 3 months post-transplant, two of whom were accompanied with dntDSA. There was one patient diagnosed with dntDSA but with a stable renal function. The eGFR of the 21 patients were 80.0 (65.2–91.3) ml/min/1.73 m² and 86.8 (61.4–102.9) ml/min/1.73 m² at 3 months and 1 year, respectively (Supplementary Figure 2).

Supplementary Table 3 summarized the potential factors affecting post-transplant outcomes, including dntDSA formation, rejection and lower eGFR. No significant correlation was found between donor-recipient height ratio and any of the post-transplant outcomes. Moreover, no significant correlation was identified between the post-transplant outcomes and the dynamic parameters of ddcfDNA, including the stable ddcfDNA level, the occurrence and duration time of ddcfDNA elevation as well as ddcfDNA flare-up.

In addition, within 3 months after kidney transplantation, there was no pathogen-proven infection and there was no any sign of recurrence of the primary disease in any recipient. No recipient experienced recurrence of primary diseases after 3 months. However, after 3 months post-transplant, three recipients were diagnosed with infection (one case of cytomegalovirus pneumonia, one case of herpetic stomatitis, one case of BKVN).

DISCUSSION
This is the first study to investigate the dynamic characteristics of ddcfDNA in pediatric kidney transplantation and to explore the impact factors of ddcfDNA dynamics. We observed a rapid decline of ddcfDNA level within 1 week after its initial increase.
post-transplant and reached a stable level <1%. Nevertheless, ddcfDNA fluctuated and presented an abnormal elevation defined as ddcfDNA flare-up after the first week post-transplant. Further analysis revealed that ddcfDNA flare-up was correlated with donor-recipient size mismatch. This study depicted the early change of ddcfDNA in pediatric KTx recipients and facilitates interpretation in its clinical application.

In this cohort of pediatric recipients, high-level ddcfDNA at day 1 rapidly declined and reached a stable level <1%. This dynamic characteristic was similar as the change pattern of ddcfDNA in adult KTx recipients (13), while there were subtle differences. Firstly, it took a longer time to reach a stable level which could be explained by more deceased donor kidneys in this study, since the adult cohort included KTx from living-related donors (13). Secondly, the stable level of ddcfDNA was lower as 0.67% in this study. One possible explanation is all donor kidneys were from deceased pediatric donors, since a higher stable ddcfDNA level was observed in participants with larger donor-weight kidneys (Table 3). Thirdly, an abnormal elevation of ddcfDNA was observed after it reached a stable level, and this significant but not subtle elevation was not observed in the adult cohorts (13, 28).

Puliyanda et al. suggested the ddcfDNA level of 1% as the cut-off value for ABMR diagnosis in pediatric KTx recipients, which was the same in adult KTx studies (9, 14). Unexpectedly,
over half of stable pediatric recipients in this study presented a ddcfDNA level >1% at day 14 and day 30 after transplantation, and ddcfDNA was over 1% in 11.1% of participants at 3 months post-transplant. These results suggest the cut-off value of 1% would significantly lead to a high false positive probability when ddcfDNA is applied for ABMR diagnosis at the early phase after kidney transplantation in children. On the other hand, we did observe a very high level of ddcfDNA (>4%) in two children with biopsy-proven ABMR, respectively, at day 70 and day 30 post-transplant (8.42 and 4.18%, Supplementary Figure 3). Therefore, we suggest careful interpretation of ddcfDNA level >1% in children early after KTx, while remaining cautious about a very high-level ddcfDNA to timely diagnosis and treatment of ABMR.

Subtle elevation of ddcfDNA was observed after reaching the stable level both in our pediatric KTx recipients and adult KTx recipients (13, 28), and such elevation was considered acceptable in clinically stable patients (11). However, we found a significant abnormal elevation pattern of ddcfDNA within 3 months post-transplant, which was inconsistent with graft function and dnDSA. Such abnormal elevation pattern was denoted as flare-up. We found that pediatric recipients with donor-recipient size mismatch were at high risk of ddcfDNA flare-up (Table 4). Severe donor-recipient size mismatch is harmful and is considered to induce graft injury (29, 30). ddcfDNA flare-up might be a result of hyperfiltration graft injury induced by donor-recipient size mismatch. Donor-recipient size mismatch was reported to increase kidney graft loss in adolescents (30, 31). Donor-recipient size mismatch led to rapid adaptive growth of pediatric donor kidneys (20), and the hyperfiltration injury might alleviate during this compensatory process, since the elevated ddcfDNA did not continuously increase and instead tended to decrease to a low level. In this study, no significant correlation was found between D/R size mismatch and the post-transplant outcomes including graft survival.

This study has the limitations of relatively small cohort size and short follow-up period. We were unable to assess the potential impact of the early abnormal ddcfDNA on long-term graft outcome. Besides, longitudinal examination of ddcfDNA with more frequent time points would facilitate full comprehension of ddcfDNA change patterns in pediatric KTx.

In summary, this study firstly demonstrated the dynamic characteristics of ddcfDNA after pediatric kidney transplantation. A high proportion of participants presented ddcfDNA >1% at day 30 post-transplant. A significant rebound (flare-up) of ddcfDNA was observed, and this may reflect the hyperfiltration injury of grafts caused by donor-recipient size mismatch. The study results suggest one should carefully interpret the clinical implication of ddcfDNA level at the early phase after pediatric kidney transplantation.

DATA AVAILABILITY STATEMENT

The data presented in the study are deposited in the NCBI Sequence Read Archive, accession number PRJNA789391.

ETHICS STATEMENT

The studies involving human participants were reviewed and approved by the Institutional Review Board of The First Affiliated Hospital of Sun Yat-sen University. Written informed consent to participate in this study was provided by the participants’ legal guardian/next of kin.

AUTHOR CONTRIBUTIONS

WN, XS, LL, HZ, and CWa: study design, data interpretation, and manuscript preparation. LL, JL, QF, CWu, RD, and SL: patient enrollment and informed consent. WN and XL: laboratory examination. WN and HZ: data analysis. WN, XS, JW, and EC: clinical data collection. SY: interpretation of pathological biopsies. XS, LL, HZ, and CWa: funding support, study supervision, and critical review of manuscript. HZ and CWa were responsible for the decision to submit for publication. All authors contributed to the article and approved the submitted version.

FUNDING

This study was supported by Science and Technology Planning Project of Guangdong Province, China (2015B020226002 and 2017A020215012), National Natural Science Foundation of China (81870511), Key Scientific and Technological Program of Guangzhou City (201803040011), Guangdong Basic and Applied Basic Research Foundation (2020A1515010884), Guangdong Natural Science Foundation (2018A030313016), Guangdong Provincial Key Laboratory on Organ Donation and Transplant Immunology (2017B030314018 and 2020B1212060026), and Guangdong Provincial International Cooperation Base of Science and Technology (Organ Transplantation, 2020A0505020003).

ACKNOWLEDGMENTS

We gratefully acknowledge Liutong Ling, Wenting Chen, and Huiting Huang from Organ Transplant Center, The First Affiliated Hospital of Sun Yat-sen University for their involvement in sample collection.

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fmed.2021.814517/full#supplementary-material

Supplementary Figure 1 | Tacrolimus trough levels at different time post-transplant in all 21 recipients. Median tacrolimus trough levels (ng/ml) at 1 week, 2 weeks, 1 month, 3 months, 6 months, 1 year was 6.7 (5.7–8.6), 7.9 (6.9–9.3), 7 (6.0–8.0), 7.1 (6.2–8.2), 7.7 (6.7–8.6), and 6.3 (5.9–7.0). Boxes depict the 25th and 75th percentiles as a box and a median line; whiskers extend to minimum or maximum. Tac, tacrolimus; wk(s), week(s); mth(s), month(s); yr, year.

Supplementary Figure 2 | The eGFR change at different time post-transplant in all 21 recipients. Median eGFR (ml/min/1.73m²) at 1 week, 2 weeks, 1 month, 3 months, 6 months, 1 year was 53.87 (40.49–77.19), 63.25 (49.27–82.15), 69.47 (53.13–74.46), 80.06 (65.18–91.25), 85.99 (69.28–102.23), and 86.78 (74.39–100.05).
REFERENCES

1. Dharnidharka VR, Fiorina P, Harmon WE. Kidney transplantation in children. N Engl J Med. (2014) 371:549–58. doi: 10.1056/NEJMra1314576

2. Wolfe RA, Ashby VB, Milford EL, Ojo AO, Ettinger RE, Agodoa LY, et al. Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. N Engl J Med. (1999) 341:1725–30. doi: 10.1056/nejm1999122321303

3. Anand A, Malik TH, Dunson J, McDonald MF, Christmann CR, Santiago AF, et al. Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. N Engl J Med. (2020) 382:1035–45. doi: 10.1056/NEJMoa2006760

4. Zhang R. Donor-specific antibodies in kidney transplant recipients. Pediatr Transplant. (2021) 25:e13999. doi: 10.1111/petr.13999

5. Zeng H, Donor-specific antibodies in kidney transplant recipients. Clin Am Soc Nephrol. (2018) 13:182–92. doi: 10.2215/cjn.00700117

6. Chu X, Cramer C, Moudgil A, Martz K, Smith J, Blyth-Hansen T, et al. Kidney transplant practice patterns and outcome benchmarks over 30 years: the 2018 report of the NAPRTCS. Pediatr Transplant. (2019) 23:e13597. doi: 10.1111/petr.13597

7. Tapia-Canelas C, Zometa R, López-Oliva MO, Jiménez C, Rivas B, Escuin F, et al. Complications associated with renal graft biopsy in transplant patients. Nefrologia. (2014) 34:115–9. doi: 10.3265/Nefrologia.pre2013.Nov.12232

8. Nankivel BJ, Chapman JR. The significance of subclinical rejection and the value of protocol biopsies. Am J Transplant. (2006) 6:2006–12. doi: 10.1111/j.1600-6143.2006.01436.x

9. Racusen LC. Protocol transplant biopsies in kidney allografts: why and when are they indicated? Clin Am Soc Nephrol. (2006) 1:144–7. doi: 10.2215/cjn.01101095

10. Bloom RD, Bromberg JS, Poggio ED, Bunnapradist S, Langone AJ, Sood P, et al. Cell-free DNA and active rejection in kidney allografts. J Am Soc Nephrol. (2017) 28:2221–32. doi: 10.1681/asn.2016091034

11. Jordan SC, Bunnapradist S, Bromberg JS, Langone AJ, Hiller D, Yee JP, et al. Donor-recipient height mismatch is associated with decreased survival in pediatric-to-adult liver transplant recipients. Liver Transpl. (2013) 19:3079–86. doi: 10.1002/lt.24537

12. Patel A, Bock MJ, Wollstein A, Nguyen K, Malerba S, Lytviri ID. Donor-recipient height ratio and outcomes in pediatric heart transplantation. Pediatr Transplant. (2016) 20:672–5. doi: 10.1111/petr.12734

13. Schwartz GJ, Muñoz A, Schneider MF, Mak RH, Kaskel F, Warady BA, et al. New equations to estimate GFR in children with CKD. J Am Soc Nephrol. (2009) 20:629–37. doi: 10.1681/asn.2008030287

14. Pierce CR, Muñoz A, Ng DK, Warady BA, Firth SL, Schwartz GJ, Age- and sex-dependent clinical equations to estimate glomerular filtration rates in children and young adults with chronic kidney disease. Kidney Int. (2017) 99:948–56. doi: 10.1016/j.kint.2020.10.047

15. Roufossie C, Simmonds N, Claessen-van Groningen M, Haas M, Henriksen KJ, Horsfield C, et al. A 2018 reference guide to the Banff classification of renal allograft pathology. Transplantation. (2018) 102:1795–814. doi: 10.1097/TP.0000000000002366

16. Gielis EM, Beirnaert C, Dendooven A, Meysman P, Laukens K, De Schrijver J, et al. Plasma donor-derived cell-free DNA kinetics after kidney transplantation using a single tube multiplex PCR assay. PLoS ONE. (2018) 13:e0208207. doi: 10.1371/journal.pone.0208207

17. Suneja M, Kuppachi S, Katz D, Hunslick L, Small split pediatric kidneys to expand the donor pool: an analysis of scientific registry of transplant recipients (SRTR) data. Transplantation. (2019) 103:2549–57. doi: 10.1097/TP.0000000000002706

18. Jackson RR, Zhou S, Ruck J, Massie AB, Holscher C, Kernodle SM, et al. Pediatric deceased donor kidney transplant outcomes under the Kidney Allocation System. Am J Transplant. (2019) 19:3079–86. doi: 10.1111/ajt.15419

19. Gander R, Asensio M, Molino JA, Royo GF, Lara LE, López M, et al. Outcome of kidney transplantation from young pediatric donors (aged less than 6 years) to young size-matched recipients. J Pediatr Urol. (2015) 11:213–20. doi: 10.1016/j.jpuro.2015.03.015

20. Su X, Shang W, Liu L, Li J, Fu Q, Feng Y, et al. Transplantation of a single kidney from pediatric donors less than 10 kg to children with poor access to transplantation: a two-year outcome analysis. BMC Nephrol. (2020) 21:250. doi: 10.1186/s12882-020-01895-6

21. Miller AJ, Kiberd BA, Alwayn JP, Oudotayo A, Tannenkore KK. Donor-recipient weight and sex mismatch and the risk of graft loss in renal transplantation. Clin Am Soc Nephrol. (2017) 12:669–76. doi: 10.2215/cjn.07660716

22. Song G, Liu J, Qiao W, Chen Y, Sun L, Ren W, et al. Regression equations of Z score and echocardiographic nomograms for coronary sinus in healthy children. Int J Cardiovasc Imaging. (2016) 32:1687–95. doi: 10.1007/s10554-016-0960-7

23. Kesseli SJ, Samoylova ML, Yerxa J, Moore CR, Cerullo M, Garo M, et al. Donor-recipient height mismatch is associated with decreased survival in pediatric-to-adult liver transplant recipients. Liver Transpl. (2021) 27:425–33. doi: 10.1002/lt.29537

24. Patel A, Bock MJ, Wollstein A, Nguyen K, Malerba S, Lytviri ID. Donor-recipient height ratio and outcomes in pediatric heart transplantation. Pediatr Transplant. (2016) 20:672–7. doi: 10.1111/petr.12734

25. Schwartz GJ, Muñoz A, Schneider MF, Mak RH, Kaskel F, Warady BA, et al. New equations to estimate GFR in children with CKD. J Am Soc Nephrol. (2009) 20:629–37. doi: 10.1681/asn.2008030287

26. Pierce CR, Muñoz A, Ng DK, Warady BA, Firth SL, Schwartz GJ, Age- and sex-dependent clinical equations to estimate glomerular filtration rates in children and young adults with chronic kidney disease. Kidney Int. (2017) 99:948–56. doi: 10.1016/j.kint.2020.10.047

27. Roufossie C, Simmonds N, Claessen-van Groningen M, Haas M, Henriksen KJ, Horsfield C, et al. A 2018 reference guide to the Banff classification of renal allograft pathology. Transplantation. (2018) 102:1795–814. doi: 10.1097/TP.0000000000002366

28. Giels EM, Beirnaert C, Dendooven A, Meysman P, Laukens K, De Schrijver J, et al. Plasma donor-derived cell-free DNA kinetics after kidney transplantation using a single tube multiplex PCR assay. PLoS ONE. (2018) 13:e0208207. doi: 10.1371/journal.pone.0208207

29. Giraud M, Foucher Y, Karam G, Labrunie Y, Kessler M, Hurault de Ligny B, et al. Kidney and recipient weight incompatibility reduces long-term graft survival. J Am Soc Nephrol. (2010) 21:1022–9. doi: 10.1681/asn.2009121296

30. Dick AA, Mercer LD, Smith JM, McDonald RA, Young B, Healey PJ. Donor and recipient size mismatch in adolescents undergoing living-donor renal transplantation affect long-term graft survival. Transplantation. (2013) 96:555–9. doi: 10.1097/TP.0b013e3182d9672c

31. Lepeyrte F, Delmas-Frenette C, Zhang X, Larivièreme Beaudoin S, Sapir-Pichhadze R, Foster BJ, et al. Donor age, donor-specific recipient mismatch, and kidney graft survival. Clin Am Soc Nephrol. (2020) 15:1455–63. doi: 10.2215/cjn.02312020
**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

The reviewer BN declared a past co-authorship with several of the authors XS, LL, JL, QF, CWu, RD, HZ, and CWa to the handling editor.

**Publisher's Note:** All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Nie, Su, Li, Fu, Li, Wu, Deng, Chen, Yang, Li, Zhang and Wang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.